Safety of NTR-101 for acute alcohol-related hepatitis
Treatments studied
Part of Digestive system clinical trials.
This study tests a new drug called NTR-101 to see if it is safe and can treat a severe type of liver inflammation caused by heavy drinking. It may help people whose liver problems are linked to a specific gut bacteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with acute alcohol-associated hepatitis (a serious liver inflammation caused by heavy drinking).
- You have a specific gut bacteria (Enterococcus faecalis) that the study drug targets.
- You are not at high risk for severe alcohol withdrawal symptoms.
- You do not have an active infection, HIV, or other serious illnesses besides the liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a protein called alpha-1 antitrypsin can help people with severe alcoholic hepatitis, a serious liver condition caused by heavy drinking. If it works, it may reduce liver damage and improve recovery.
This trial is testing a new medicine called NTR-1011 to see if it is safe and tolerable for people with lupus or rheumatoid arthritis. If you have active lupus or RA and are on a stable treatment plan, you may be able to join.
This study tests a new drug called MRG-001 to see if it helps people with alcoholic hepatitis. The trial is looking for patients who have severe alcoholic hepatitis (with jaundice starting in the last 8 weeks) and have been drinking heavily for at least 6 months.
This trial looks at the gut bacteria (microbiome) in people with severe alcoholic hepatitis to understand how it affects the illness. It may help doctors find better ways to treat this condition.
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
This early-phase study is testing a treatment approach for people with alcoholic hepatitis (liver inflammation caused by heavy alcohol use). It may help by improving liver function and outcomes in people who meet specific lab and health criteria.
Hear when a new Alcohol-Associated Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.